BioCentury | Jul 21, 2016
Distillery Therapeutics

Therapeutics: Tumor necrosis factor receptor superfamily member 11a (RANK; TNFRSF11A; CD265); receptor activator of NF-κB ligand (RANKL; TNFSF11); breast cancer

...of the bone and hypercalcemia associated with malignant tumor. Ablynx N.V. and Eddingpharm Inc. have ALX-0141...
BioCentury | Jul 9, 2015
Distillery Therapeutics

Therapeutics: Receptor activator of NF-κB ligand (RANKL; TNFSF11); macrophage colony-stimulating factor 1 (CSF1; M-CSF)

...bone cancer and have it approved for musculoskeletal indications. Ablynx N.V. and Eddingpharm Inc. have ALX-0141...
BioCentury | Sep 8, 2014
Company News

Ablynx, Eddingpharm deal

...commercialize ALX-0141 , which had completed a Phase I trial to treat bone loss-related disorders. ALX-0141...
BioCentury | Oct 21, 2013
Finance

Highlights of weekly biotech stock moves

...to €7.58 on Friday after granting Eddingpharm Inc. exclusive, Chinese rights to develop and commercialize ALX-0141...
...million ($2.7 million) up front and is eligible for undisclosed milestones, plus tiered double-digit royalties. ALX-0141...
BioCentury | Oct 21, 2013
Company News

Ablynx, Eddingpharm deal

...Ablynx granted Eddingpharm exclusive rights in China and Taiwan to develop and commercialize ALX-0141 , which...
...development, registration and commercialization in China. Ablynx will have rights to data generated by Eddingpharm. ALX-0141...
BioCentury | Oct 19, 2013
Company News

Eddingpharm gets Chinese rights to ALX-0141 from Ablynx

...granted Eddingpharm Inc. (Shanghai, China) exclusive rights in China and Taiwan to develop and commercialize ALX-0141...
...development, registration and commercialization in China. Ablynx will have rights to data generated by Eddingpharm. ALX-0141...
BioCentury | Sep 1, 2011
Cover Story

IL-20's osteoporosis connection

...need to see the antibody's effects confirmed in nonhuman primates or other higher-order species." Ablynx's ALX-0141...
BioCentury | Jan 17, 2011
Clinical News

ALX-0141: Additional Phase I data

...women showed that 4 of 6 subjects receiving a single subcutaneous injection of 1 mg/kg ALX-0141...
...of bone resorption activity, at 9 months. Subjects received single subcutaneous injections of 0.003-1 mg/kg ALX-0141...
...120 days of follow-up (see BioCentury, Sept. 27, 2010). Ablynx N.V. (Euronext:ABLX), Ghent, Belgium Product: ALX-0141...
BioCentury | Oct 14, 2010
Distillery Therapeutics

Indication: Cancer

...is approved to treat osteoporosis and is in registration to treat bone cancer. Ablynx N.V.'s ALX-0141...
BioCentury | Sep 27, 2010
Clinical News

ALX-0141: Phase I data

...placebo-controlled Phase I trial in 42 healthy postmenopausal women, single subcutaneous injections of 0.003-1 mg/kg ALX-0141...
...I collagen (CTX-1) , a biomarker of bone resorption activity, were observed in all 31 ALX-0141-treated...
...observed in 27 subjects at day 120 of follow-up. Ablynx N.V. (Euronext:ABLX), Ghent, Belgium Product: ALX-0141...
Items per page:
1 - 10 of 14